Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38^th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") to be held in San Diego, CA, from November 1-5^th, 2023.

The company will present an update from its Phase 1/2 ABILITY Study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, a long-acting, beta-enhanced IL-2 Superkine. In addition, pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 superkine, will also be presented at the conference.

Poster presentation details:

• Title: Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a Phase 1/2 trial with MDNA11 in patients with advanced solid tumors
• Poster Number: 760
• Presentation Date: Saturday, November 4, 2023, 9:00 am to 8:30 pm PDT
  
  

• Title: Characterization of a tumor-targeting and activatable T-MASK platform to enhance tumor accumulation and tolerability of potent immune modulators
• Poster Number: 1071
• Presentation Date: Friday, November 3, 2023, 9:00 am to 7:00 pm PDT
  
  

About Medicenna
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class class-empowered superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage BiSKITstm program (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically "cold" tumors.